title: Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis.
abstract: New gene expressed in prostate (NGEP) is a newly diagnosed prostate-specific gene that is expressed only in normal prostate and prostate cancer cells. Discovery of tissue-specific markers may promote the development of novel targets for immunotherapy of prostate cancer. In the present study, the staining pattern and clinical significance of NGEP were evaluated in a series of prostate tissues composed of 123 prostate cancer, 19 high-grade prostatic intraepithelial neoplasia and 44 samples of benign prostate tissue included in tissue microarrays using immunohistochemistry. Our study demonstrated that NGEP localized mainly in the apical and lateral membranes and was also partially distributed in the cytoplasm of epithelial cells of normal prostate tissue. All of the examined prostate tissues expressed NGEP with a variety of intensities; the level of expression was significantly more in the benign prostate tissues compared to malignant prostate samples (P value <0.001). Among prostate adenocarcinoma samples, a significant and inverse correlation was observed between the intensity of NGEP expression and increased Gleason score (P = 0.007). Taken together, we found that NGEP protein is widely expressed in low-grade to high-grade prostate adenocarcinomas as well as benign prostate tissues, and the intensity of expression is inversely proportional to the level of malignancy. NGEP could be an attractive target for immune-based therapy of prostate cancer patients as an alternative to the conventional therapies particularly in indolent patients.
authors: Immunology Research Centre, Iran University of Medical Sciences, Tehran, Iran.
authors: Monireh
authors: M
authors: Mohsenzadegan
authors: Zahra
authors: Z
authors: Madjd
authors: Mojgan
authors: M
authors: Asgari
authors: Maryam
authors: M
authors: Abolhasani
authors: Mehdi
authors: M
authors: Shekarabi
authors: Jaleh
authors: J
authors: Taeb
authors: Ahmad
authors: A
authors: Shariftabrizi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000075368:Anoctamins; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis* / Q000235:genetics; D008875:Middle Aged; D060787:Neoplasm Grading; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D064129:Prostatic Neoplasms, Castration-Resistant / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D046888:Tissue Array Analysis
chemical_list: C498181:ANO7 protein, human; D000075368:Anoctamins; D008565:Membrane Proteins
references: Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7
references: 22918924
references: Korean J Urol. 2012 Dec;53(12):826-9
references: 23301125
references: Nat Med. 1998 Jul;4(7):844-7
references: 9662379
references: Oncotarget. 2011 Dec;2(12):1176-90
references: 22202492
references: Clin Cancer Res. 2005 May 1;11(9):3353-62
references: 15867235
references: Cancer Res. 1994 Apr 1;54(7):1807-11
references: 7511053
references: BJU Int. 2013 May;111(5):753-60
references: 23464824
references: Histopathology. 2012 Jan;60(1):87-117
references: 22212080
references: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3059-64
references: 14981236
references: PLoS One. 2009 Dec 04;4(12):e7682
references: 19997627
references: Cancer Res. 2008 Aug 1;68(15):6306-12
references: 18676855
references: Biochem Biophys Res Commun. 2000 Sep 7;275(3):783-8
references: 10973799
references: Am J Physiol Cell Physiol. 2012 Feb 1;302(3):C482-93
references: 22075693
references: Nat Biotechnol. 2005 Sep;23(9):1073-8
references: 16151394
references: Cancer Res. 2007 Feb 15;67(4):1594-601
references: 17308099
references: Clin Dev Immunol. 2012;2012:124187
references: 22778760
references: Cell J. 2011 Fall;13(3):155-62
references: 23508738
references: Int J Clin Oncol. 2003 Aug;8(4):193-9
references: 12955573
references: Int J Mol Med. 2005 Nov;16(5):919-24
references: 16211264
references: Prostate. 2009 May 1;69(6):571-84
references: 19143030
references: Peptides. 2011 Jun;32(6):1097-102
references: 21539876
references: J Physiol. 2009 May 15;587(Pt 10):2127-39
references: 19015192
references: Cancer Immunol Immunother. 2010 Jan;59(1):63-71
references: 19495750
references: Ann Oncol. 2007 Mar;18(3):581-92
references: 17287242
references: Annu Rev Med. 2007;58:221-37
references: 17059365
references: Histopathology. 2007 Mar;50(4):472-83
references: 17448023
references: Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):749-53
references: 8570628
references: Nan Fang Yi Ke Da Xue Xue Bao. 2009 Oct;29(10):2135-7
references: 19861285
references: Clin Cancer Res. 2010 Aug 1;16(15):4046-56
references: 20562209
references: Nat Rev Immunol. 2010 Aug;10(8):580-93
references: 20651745
references: N Engl J Med. 2010 Jul 29;363(5):411-22
references: 20818862
references: Fetal Pediatr Pathol. 2013 Jun;32(3):192-204
references: 22830353
references: Arch Pathol Lab Med. 1985 Aug;109(8):716-21
references: 3893381
references: Semin Oncol. 2005 Dec;32(6):549-55
references: 16338420
references: Curr Pharm Des. 2006;12(7):807-17
references: 16515497
references: Clin Cancer Res. 2008 Aug 15;14(16):5284-91
references: 18698048
references: Am J Surg Pathol. 2005 Sep;29(9):1228-42
references: 16096414
references: Expert Opin Ther Targets. 2005 Jun;9(3):561-70
references: 15948673
references: J Urol. 2004 Dec;172(6 Pt 2):2532-8
references: 15538202
references: Urology. 1999 Dec;54(6A Suppl):1-7
references: 10606277
references: Expert Rev Vaccines. 2003 Aug;2(4):483-93
references: 14711334
references: Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40
references: 9465086